Astrazeneca Pharma India Ltd. (ASTRAZEN): Astrazeneca Pharma India Share Price hits fresh 52-week low

Published: 24 August 2026 at 10:00 AM IST

Astrazeneca Pharma India Share Price fell to Rs 7,378.05, down 0.44% today, marking a fresh 52-week low. The company’s market capitalisation stands at Rs 18,526.25 crore.

Astrazeneca Pharma India Share Price is in focus after the stock touched Rs 7,378.05, its fresh 52-week low, and closed down 0.44% on the day. The move left Astrazeneca Pharma India Ltd. (ASTRAZEN) with a market capitalisation of Rs 18,526.25 crore, a level that places today’s price action squarely in the one-year low discussion for Astrazeneca Pharma India Share Price. The first read from the supplied data is simple: the event is verified by the price print, but it does not establish a company-specific catalyst. That makes the stock news relevant for investors tracking Astrazeneca Pharma India Share Price Today, especially as the session also reflected a narrow intraday range and a close at the low of the day.

For Univest readers, this is an event-led update on Astrazeneca Pharma India Share Price and not a forecast. The supplied figures show a daily decline, a fresh yearly low and a high-valuation profile that will matter to investors comparing Astrazeneca Pharma India Stock News with broader healthcare peers. The discussion below focuses on verified price action, fundamentals, sector positioning and peer benchmarks, so the article can serve as a practical Astrazeneca Pharma India Share Price Today reference without adding unsupported explanations.

Astrazeneca Pharma India Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 7,378.05
Previous Close	Rs 7,410.5
Today's Move	Rs -32.45 (-0.44%)
Open	Rs 7,400.05
High	Rs 7,449.7
Low	Rs 7,378.05
Turnover	Rs 0.1 crore
Market Capitalisation	Rs 18,526.25 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 7,378.05. versus the previous close of Rs 7,410.5, a fall of 0.44%. The stock opened at Rs 7,400.05, reached Rs 7,449.7, touched Rs 7,378.05.

Astrazeneca Pharma India Share Price opened at Rs 7,400.05, moved to an intraday high of Rs 7,449.70 and a low of Rs 7,378.05, then settled at Rs 7,378.05. Against the previous close of Rs 7,410.50, the stock ended lower by Rs 32.45, or 0.44%. Because the close matched the day’s low and the stock also matched its fresh 52-week low of Rs 7,378.05, the session qualifies as a clear Astrazeneca Pharma India Share Price update for traders and long-term trackers alike.

The movement was not large in percentage terms, but it was important in context because the stock has now printed a new one-year low. In share market today terms, that puts Astrazeneca Pharma India among stocks in news and 52 week low stocks that investors may track for valuation, earnings and sector comparisons. The turnover for the session was Rs 0.1 crore, and the market capitalisation remained at Rs 18,526.25 crore. For anyone following Astrazeneca Pharma India Share Price Live, today’s price action confirms that the stock stayed under pressure from its own recent range and closed exactly at the low of the session. Univest highlights this as a factual market event rather than a signal about what must happen next.

This is the kind of price action that often keeps a stock on watchlists in top losers today screens and market news summaries, even when the day’s percentage move is modest. For Astrazeneca Pharma India Share News readers, the key point is the fresh 52-week low itself and the fact that the stock is now trading below the latest close from the prior session. The next question is whether the valuation and fundamentals justify the share price, which leads naturally into Astrazeneca Pharma India Fundamental Analysis.

Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 18,526.25 crore
P/E Ratio	109.22x
P/B Ratio	20.49x
ROE	23.02%
ROCE	31.24%
EPS	Rs 67.85
Book Value Per Share	Rs 361.68
Dividend Yield	0.49%

Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 109.22x, P/B 20.49x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.

Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 18526.25 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 109.22x, P/B at 20.49x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.49%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 30.84x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	109.22x
Benchmark Median P/E	30.84x
Benchmark Average P/E	45.96x
Benchmark P/E Range	2.94x to 689.27x
Company P/B Ratio	20.49x
Benchmark Median P/B	2.57x
Company ROE	23.02%
Benchmark Median ROE	11.78%
Company ROCE	31.24%
Benchmark Median ROCE	13.65%
Company Market Capitalisation	Rs 18,526.25 crore
Benchmark Median Market Cap	Rs 506.13 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 109.22x, which is above the benchmark median of 30.84x, a difference of +254.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.78%, a difference of +95.42%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.65%, a difference of +128.86%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Eris Lifesciences Ltd.	ERIS	18,369.22	28.53	4.54	13.81	13.59
Suven Pharmaceuticals Ltd.	COHANCE	17,698.95	166.61	4.58	14.2	18.44
Caplin Point Laboratories Ltd.	CAPLIPOINT	19,444.55	29.22	5.16	21.72	26.22
Glenmark Life Sciences Ltd.	ALIVUS	16,556.96	27.46	4.75	18.41	24.61
Concord Biotech Ltd.	CONCORDBIO	16,417.42	59.62	7.92	13.54	18.04

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 109.22x compared with the displayed peer median of 29.22x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 14.2% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 18.44%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 18,526.25 crore. Among the 5 peers shown, 1 has a larger market capitalisation.

Why Investors Are Watching Astrazeneca Pharma India

• Astrazeneca Pharma India Share Price touched Rs 7,378.05, which is a fresh 52-week low and the day’s closing price.
• The stock closed 0.44% lower than the previous close of Rs 7,410.50.
• Market capitalisation stands at Rs 18,526.25 crore, with a P/E ratio of 109.22 and a P/B ratio of 20.49.
• ROE is 23.02% and ROCE is 31.24%, both above the supplied industry benchmarks.
• Revenue was Rs 6,827.9 crore in Jun 26 and net profit was Rs 379.3 crore in Jun 26.

About Astrazeneca Pharma India

Astrazeneca Pharma India Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied company financials cover quarterly revenue and net profit, along with annual return ratios, EPS, book value and dividend yield. For readers following Astrazeneca Pharma India Share Price, this company overview provides the factual business context that can be linked with market cap, valuation and return metrics.

Univest uses this section to keep Astrazeneca Pharma India Stock News grounded in verified company data. The company description is limited to the sector and industry classification supplied in the dataset, so the article stays within the facts available for Astrazeneca Pharma India Share Price and related market updates.

Track Astrazeneca Pharma India Share Price on Univest

Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.

Readers can track Astrazeneca Pharma India Share Price on Univest for live price updates, company financials, shareholding pattern, market capitalisation, 52-week levels and benchmark comparisons. Univest also presents Astrazeneca Pharma India Stock News, Astrazeneca Pharma India Share News and Astrazeneca Pharma India Fundamental Analysis in one place so users can follow the same stock across price action and company metrics.

Frequently Asked Questions

Why did Astrazeneca Pharma India Share Price hit a fresh 52-week low?

Ans. The supplied data confirms that Astrazeneca Pharma India Share Price touched Rs 7,378.05, a fresh 52-week low, but it does not establish a company-specific catalyst. The move is verified by the session’s price print and close.

What is Astrazeneca Pharma India Share Price today?

Ans. Astrazeneca Pharma India Share Price today is Rs 7,378.05. The stock finished 0.44% lower than the previous close of Rs 7,410.50 and also marked the low of the day at the same level.

What is Astrazeneca Pharma India market capitalisation?

Ans. Astrazeneca Pharma India has a market capitalisation of Rs 18,526.25 crore. That figure is above the industry median market cap in the supplied benchmark set and helps frame the stock’s size.

How expensive is Astrazeneca Pharma India Share Price on valuation metrics?

Ans. Astrazeneca Pharma India trades at a P/E of 109.22 and a P/B of 20.49. Both are well above the supplied healthcare industry medians, so the valuation sits at a premium in the benchmark set.

What do ROE and ROCE show for Astrazeneca Pharma India?

Ans. ROE stands at 23.02% and ROCE at 31.24%. Both are above the supplied industry median and average, which gives useful context when reading Astrazeneca Pharma India Share Price alongside profitability metrics.

What are the EPS, book value and dividend yield for Astrazeneca Pharma India?

Ans. EPS is Rs 67.85, book value is Rs 361.68 per share and dividend yield is 0.49%. These are core fundamentals that help readers assess Astrazeneca Pharma India Share Price against earnings, asset base and payout history.

How does Astrazeneca Pharma India compare with peers?

Ans. Astrazeneca Pharma India’s market cap of Rs 18,526.25 crore is in line with the supplied peer set, while its P/E is higher than most listed peers in the comparison group. Its return ratios are also stronger than several peers.

Is Astrazeneca Pharma India Share Price part of healthcare stock news today?

Ans. Yes. Astrazeneca Pharma India Share Price is part of healthcare stock news today because it hit a fresh 52-week low and sits within the Pharmaceuticals & Drugs industry, where investors compare valuation and return ratios.

What quarterly financials were supplied for Astrazeneca Pharma India?

Ans. The supplied quarterly data shows Jun 26 revenue at Rs 6,827.9 crore and net profit at Rs 379.3 crore. Earlier quarters were also provided, allowing a factual view of company financials around Astrazeneca Pharma India Share Price.

What should readers monitor next for Astrazeneca Pharma India Share Price?

Ans. Readers should monitor future price action, company financials, valuation multiples and sector comparisons. The current update confirms a fresh 52-week low, but it does not provide a forecast for Astrazeneca Pharma India Share Price.